Sun Pharmaceutical Industries Ltd. reported a 36.2% year-on-year (YoY) decline in consolidated net profit to \u20b91,989 crore for the second quarter of FY27, compared with \u20b93,118 crore in the corresponding quarter last year. The decline was primarily due to a one-time exceptional charge during the quarter.<\/p>\n\n\n\n
Despite the fall in reported profit, the pharmaceutical major recorded healthy revenue growth. Consolidated revenue from operations increased 11.9% YoY to \u20b916,199 crore in Q2 FY27, against \u20b914,478 crore in Q2 FY26.<\/p>\n\n\n\n
The company\u2019s profit, excluding the one-time charge, increased 6.3% YoY to \u20b94,428 crore, indicating growth in underlying earnings.<\/p>\n\n\n\n
Sun Pharma’s reported profitability was affected by a one-time charge of approximately \u20b91,269 crore during the September quarter.<\/p>\n\n\n\n
The charge was largely associated with the company’s proposed acquisition of US-based Organon & Co. and provisions related to India’s new labour code.<\/p>\n\n\n\n
Consequently, reported consolidated net profit declined despite growth in revenue. Excluding the one-time charge, the company’s net profit stood at \u20b94,428 crore, registering a 6.3% increase compared with the year-ago period.<\/p>\n\n\n\n
The distinction between reported and adjusted profit is important when assessing the company’s operating performance for the quarter.<\/p>\n\n\n\n
Sun Pharma’s India business remained a key growth driver during Q2 FY27. Sales in the domestic market increased 17.3% year-on-year.<\/p>\n\n\n\n
The performance reflects continued growth in the company’s domestic pharmaceutical business and its presence across multiple therapeutic segments.<\/p>\n\n\n\n
India remains the company’s largest market and contributed positively to overall revenue growth during the quarter.<\/p>\n\n\n\n
The company’s US business reported a comparatively weaker performance, with sales declining 8.2% year-on-year.<\/p>\n\n\n\n
The decline in the US market partially offset the growth recorded in India and other markets. The US remains an important market for Sun Pharma, particularly for its generics and specialty medicines portfolio.<\/p>\n\n\n\n
Sun Pharma’s global specialty business recorded sales growth of 6.9% to US$356 million during the quarter. Specialty products accounted for 21.1% of the company’s total sales.<\/p>\n\n\n\n
The business includes medicines across areas such as dermatology, oncology and other specialised therapeutic categories. Growth in this segment remains an important part of the company’s strategy to strengthen its global presence and product portfolio.<\/p>\n\n\n\n
Sun Pharma’s proposed acquisition of US-based Organon & Co. is a significant strategic development for the company.<\/p>\n\n\n\n
The transaction is intended to strengthen Sun Pharma’s global presence and expand its position in the pharmaceutical market. However, acquisition-related expenses and other exceptional provisions affected the company’s reported earnings in Q2 FY27.<\/p>\n\n\n\n
The impact of the transaction and its eventual contribution to the company’s business will remain important factors to watch in the coming quarters.<\/p>\n\n\n\n
Sun Pharma’s Q2 FY27 performance presented a mixed picture. Revenue increased nearly 12% year-on-year, supported by strong growth in the domestic business and an expanding specialty portfolio. However, reported net profit declined 36.2% due to the one-time exceptional charge.<\/p>\n\n\n\n
Excluding this charge, net profit grew 6.3%, highlighting the difference between reported earnings and underlying profitability. Going forward, investors and market participants will monitor the company’s domestic growth, US business performance, specialty portfolio and progress on the proposed Organon acquisition.<\/p>\n\n\n\n